Information Provided By:
Fly News Breaks for September 4, 2019
Sep 4, 2019 | 06:27 EDT
Roth Capital analyst Tony Butler started Replimune Group with a Buy rating and $20 price target. The analyst is hopeful that oncolytic viruses, such as the company's RP1, in combination with immune checkpoint inhibitors could widen the population of patients who may benefit from ICIs. His price target is driven by Replimune's commercial opportunities of RP1 in the treatment of cutaneous squamous cell carcinoma and urothelial carcinoma in the U.S. and Europe.
News For REPL From the Last 2 Days
There are no results for your query REPL